NASDAQ:WVE WAVE Life Sciences Q3 2026 Earnings Date & Estimates $3.37 -0.05 (-1.46%) Closing price 10/21/2026 04:00 PM EasternExtended Trading$3.34 -0.03 (-0.89%) As of 05:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. WAVE Life Sciences is estimated to report Q3 2026 earnings on Tuesday, October 27, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 27, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from WAVE Life Sciences in Q3 2026WAVE Life Sciences is expected to post earnings of -$0.34 per share on revenue of $4.51 million. In the same quarter a year earlier WAVE Life Sciences reported -$0.32 per share on revenue of $7.61 million. WAVE Life Sciences last reported on July 30, 2026, posting -$0.34 per share and missing the -$0.2998 consensus estimate. WAVE Life Sciences has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.34Expected Revenue$4.51 millionPrior-Year EPS-$0.32Prior-Year Revenue$7.61 millionExpected Revenue Growth-40.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.34 (Missed by -$0.0403)Last Quarter Revenue$2.27 millionEPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report WAVE Life Sciences Q3 2026 Earnings FAQ When does WAVE Life Sciences report Q3 2026 earnings? WAVE Life Sciences (NASDAQ:WVE) is estimated to report Q3 2026 earnings on Tuesday, October 27, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is WAVE Life Sciences' Q3 2026 earnings call? WAVE Life Sciences' Q3 2026 earnings conference call is scheduled for Tuesday, October 27, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for WAVE Life Sciences? Analysts expect WAVE Life Sciences to post earnings of -$0.34 per share for Q3 2026. How much revenue is WAVE Life Sciences expected to report? The consensus revenue estimate for WAVE Life Sciences is $4.51 million for Q3 2026. WAVE Life Sciences Earnings HeadlinesWave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026October 20 at 8:30 AM | globenewswire.comWave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026October 19 at 8:30 AM | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 22 at 1:00 AM | Weiss Ratings (Ad)Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth ViewsOctober 17, 2026 | finance.yahoo.comWave Life Sciences Inc.October 16, 2026 | money.usnews.comWave Life Sciences to Present at Chardan’s 10th Annual Healthcare ConferenceOctober 13, 2026 | markets.businessinsider.comSee More WAVE Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like WAVE Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on WAVE Life Sciences and other key companies, straight to your email. Email Address About WAVE Life SciencesWAVE Life Sciences (NASDAQ:WVE) (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases. Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders. WAVE’s development portfolio has included WVE-006, an investigational RNA-editing medicine for alpha-1 antitrypsin deficiency, and programs designed to selectively target disease-associated genes or transcripts. Founded in 2012, WAVE Life Sciences is headquartered in Lexington, Massachusetts, and serves patients and partners through research and clinical-development activities in the United States and internationally. The company is led by President and Chief Executive Officer Paul Bolno.View WAVE Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX Earnings Launch: High Margins Fund AI AmbitionsGM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?Synchrony Aces The Quarter As Credit Fears FadeHigher Rates Are Sending Investors to These 3 Dividend KingsServiceNow Orchestrates AI's Next Act—Can Earnings Deliver?Swiping to Record Highs: Why Visa Remains a FortressDrone Stocks Have Burned Investors—Are These 4 Different? Upcoming Earnings ENI (10/23/2026)SLB (10/23/2026)American Express (10/23/2026)Infosys (10/23/2026)Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
